Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, single center, and a single arm phase II study to evaluate the
clinical response and safety of perioperative S-1 plus docetaxel. Perioperative chemotherapy
is composed of 3 cycles of preoperative S-1/docetaxel and 3 cycles of postoperative
S-1/docetaxel.Chemotherapy regimen:
- S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
- Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8